Hemispherx Biopharma | $HEB

8-9-16 Company Focus: Hemispherx BioPharma Inc. (NYSE: HEB)

8-9-16 - SCN's Jane King Interviews CEO Thomas Equels of Hemispherx BioPharma Inc. (NYSE: HEB)


Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company’s primary products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; and Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts. It is also developing Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

Get the Latest Videos

Small Cap Movers


PNK : DPWW - 26 Aug, 11:48am
-0.16 (-27.59%) After Hours:
Open 0.56 Mktcap 17.90M
High 0.56 52wk Hight 0.56
Low 0.42 52wk Low 0.42
Vol 600 Avg Vol
Eps P/e
Currency: USD


PNK : BKYI - 26 Aug, 9:41am
+0.00 (+0.00%) After Hours:
Open 0.24 Mktcap 15.93M
High 0.24 52wk Hight 0.31
Low 0.23 52wk Low 0.10
Vol 3317 Avg Vol 133009
Eps P/e
Currency: USD

Chanticleer Holdings, Inc.

NCM : HOTR - 26 Aug, 3:58pm
-0.0081 (-1.9378%) After Hours:
Open 0.4330 Mktcap 9.00M
High 0.4500 52wk Hight 1.6000
Low 0.3800 52wk Low 0.3600
Vol 176789 Avg Vol 78875
Eps -0.1300 P/e
Currency: USD

NanoViricides, Inc. NEW Common

ASE : NNVC - 26 Aug, 4:00pm
-0.01 (-0.65%) After Hours:
Open 1.57 Mktcap 89.28M
High 1.58 52wk Hight 3.44
Low 1.52 52wk Low 0.96
Vol 102300 Avg Vol 107325
Eps -0.20 P/e
Currency: USD

Sign Up For Our Newsletter